FDA granted 510(k) clearance to GE HealthCare’s MIM Software tool to calculate the absorbed dose of radionuclides using a Monte Carlo method.
FDA has launched a venture in onshoring domestic drug development called the Precheck Pilot Program.
FDA grants clearance for radiation oncology tool to calculate absorbed dose of radionuclides
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA announced recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase deficiency.
The reviews of two drugs granted priority review via FDA’s new priority voucher program, Commissioner’s National Priority Voucher (CNPV) Pilot Program, have been delayed.
FDA has approved Darzalez Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.
A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
Over his five decades as a radiation oncologist, Bernie Lewinsky has been collecting the relics of radiotherapy.
